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Abstract
In sepsis, lipopolysaccharide (LPS) activates toll-like receptor 4 to stimulate the release of
inflammatory cytokines (e.g. tumor necrosis factor-alpha, TNF-α), leading to cardiac
dysfunction. Regulator of G protein signaling 2 (RGS2) limits G protein-coupled receptor
signaling by increasing the rate of G protein deactivation or inhibiting G protein-effector
interactions. We hypothesized that RGS2 deficiency would enhance proinflammatory
responses in endotoxemia. Adult wild-type and RGS2-/- C57BL/6 mice and neonatal
cardiomyocytes were treated with LPS and assessed for inflammatory responses and cardiac
function. Myocardial TNF-α expression was higher in RGS2-/- mice during endotoxemia.
Additionally, cardiac function was impaired in RGS2-/- mice. Phosphorylated p38 levels were
higher in the RGS2-/- myocardium in endotoxemia. In vitro, TNF-expression was higher in
RGS2-/- cardiomyocytes after LPS stimulation. Our study suggests that RGS2 is
cardioprotective and inhibits proinflammatory signaling via p38 in sepsis. Thus, this study
suggests a novel therapeutic target for the clinical treatment of sepsis.

Keywords
sepsis, regulator of G protein signaling 2 (RGS2), cardiac dysfunction, endotoxemia, TNF-α,
inflammatory cytokine release
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Summary for Lay Audience
Sepsis is a major cause of death globally and of in-hospital mortality in Canada. It is caused
by an improper response to infection, resulting in inflammation and organ failure. However,
there are no drugs specifically targeted for sepsis. The bacterial component, lipopolysaccharide
(LPS), causes sepsis by stimulating a proinflammatory response, leading to heart dysfunction
and patient death. G protein-coupled receptors (GPCRs) are a family of receptors found in
many tissues that regulate a variety of cellular processes. GPCR activities can be limited by
regulator of G protein signaling 2 (RGS2). While both RGS2 regulated GPCR signaling and
LPS induced inflammatory pathway are well established, how the two signaling pathways
interact is not known. The aim of this thesis was to determine the role of RGS2 in LPS induced
inflammation in the heart, and identify factors modulated by RGS2. Adult wild-type and RGS2
deficient mice were challenged with LPS, while newborn mouse cardiac cells were isolated
and treated with LPS. They were then assessed for inflammatory responses by measuring the
levels of TNF-α, a proinflammatory factor. Results show that TNF-α expression was induced
by LPS in wild-type mice, and the response was further enhanced in the heart of RGS2
deficient mice. Similarly, LPS-induced TNF-α expression was higher in RGS2 deficient
cardiomyocytes. Furthermore, LPS-induced activity of p38, an inflammatory mediator, was
also higher in the heart of RGS2 deficient mice. Notably, heart dysfunction was worse in RGS2
deficient mice in sepsis. In conclusion, RGS2 is protective and can inhibit the proinflammatory
response in sepsis. This thesis may open up new strategies in the design of drugs for the
treatment of sepsis.
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Chapter 1
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Introduction
Sepsis

Sepsis is a life-threatening condition caused by a dysregulated host response to infection.1
It is a leading cause of death due to infection globally and occurs in 2-11% of patients in
hospitals and intensive care units.2,3 Currently, one in five deaths worldwide is due to
sepsis.4 While there has been a decreasing trend in sepsis burden globally from 1990-2017,
an estimate of 11 million sepsis-related deaths were reported for 2017.4 Among these cases,
males had higher mortality than females.4 The population at risk include young children as
well as adults 65 years and older, which is a cause for concern with the global aging
population.4,5 Sepsis cases and mortality rates are different depending on location, with the
highest impact on countries with low socio-demographic index, which is an indicator of
socio-demographic development.4 Countries such as sub-Saharan Africa, Oceania, south
Asia, east Asia, and southeast Asia had the highest burden in 2017, which may be due to
lack of access to supportive treatments.4 Survivors of sepsis often experience long term
consequences that decrease their quality of life.6–8 Sepsis is independently associated with
increased risk of cognitive impairment and functional limitations, which correlates with
increased healthcare needs, depression, and mortality.8 Thus, in addition to implications
for patients and their families, sepsis has a major impact on the healthcare system.
Severe cases of sepsis may lead to multi-organ failure and septic shock.1,9 In North America
and Europe, approximately 7% of admitted intensive care unit patients have septic shock.10
Septic shock is defined as a subset of sepsis, in which circulatory and metabolic
abnormalities increase mortality. According to the most recent Sepsis-3 definition, clinical
criteria for septic shock include the presence of both hypotension and hyperlactemia.1
Specifically, septic shock patients are identified as having enduring hypotension that
requires vasopressors to sustain mean arterial pressure (MAP) above 65 mmHg, and a
serum lactate level above 2 mmol/L (18 mg/dL) despite volume resuscitation treatment.1,11
The first-line vasopressor used for septic shock is norepinephrine, and it is recommended

2

to be used alongside fluid resuscitation to attain the target MAP ≥ 65 mmHg.12 The
presence of both hypotension and hyperlactemia broadly encompasses cardiovascular and
cellular impairment and is correlated with significantly higher mortality. In North America
and Europe, septic shock has a mortality rate of about 38%. Globally, hospital mortality
for such patients is above 40%.1,10
Sources of infection that may lead to sepsis include bacterial, fungal, viral, and parasitic
pathogens.4 While an appropriate immune response is necessary to combat and clear
infections to protect the host, an improper immune response can be harmful to the host.
This aberrant immune response has two phases. In the initial stage of sepsis, patients often
show a drastic increase in proinflammatory response as characterized in systemic
inflammatory response syndrome (SIRS). As sepsis progresses, patients enter an
immunosuppressive state, characterizing the compensatory anti-inflammatory response
syndrome (CARS).13 The excessive inflammation found in the SIRS causes collateral
tissue and organ damage, while the CARS stage is thought to be responsible for increasing
patient susceptibility to secondary infections.14 While sepsis is described as two stages, it
is more complex in humans as both phases follow a variable time course and do not always
appear at separate times. Due to the heterogeneity of sepsis, this makes it difficult to study
in humans.
In the past two decades, studies have reported higher survival rates which have been
attributed to improvements in supportive therapies for septic shock patients.15,16 Currently,
there are no approved targeted therapeutics to directly combat sepsis. Rather, treatments
such as antibiotics and fluid resuscitation are focused on the cause of the infection and life
support measures, respectively.15,17

1.1.1 Endotoxemia as a model of sepsis
The pathogenesis of sepsis is caused by a pathogen that can trigger a systemic
inflammatory response – 50% of which are of microbial origin.18 Of these, gram-positive
and gram-negative bacteria are responsible for approximately 50% and 40% of infections
respectively.3 Endotoxin/lipopolysaccharide (LPS) found on the gram-negative bacteria
contributes to sepsis pathogenesis through a well-defined intracellular signaling cascade.19

3

It activates downstream pathways of toll-like receptor 4 (TLR4) to stimulate the release of
proinflammatory cytokines. Murine endotoxemia models have been used for almost 100
years to simulate sepsis in humans.20 While it does not fully recapitulate septic conditions
in humans, endotoxemia is a scientifically useful model for investigating specific pathways
and mechanisms during septic immune responses.20

Sepsis-induced cardiac dysfunction
Globally, close to half of all sepsis-related deaths occur due to an underlying injury or noncommunicable disease with sepsis complications.4 Organ dysfunction in sepsis most
commonly compromises the respiratory and cardiovascular systems. Cardiovascular
effects primarily result in an elevated serum lactate level or hypotension. SIRS may
contribute to persistently elevated lactate levels post cardiac arrest.11 Additionally, patients
with cardiogenic shock after heart surgery may have increased lactate levels due to elevated
lactate production.21 Serum lactate level is an important indicator in predicting mortality in
cardiogenic shock patients treated with extracorporeal membrane oxygenation.22 Similarly,
hypotension persists as sepsis progresses, and myocardial dysfunction may occur.14
Myocardial dysfunction is a common complication of septic shock and a major predictor
of mortality in sepsis, and occurs in 40% of sepsis patients.23–25 The mortality rate of these
patients can be as high as 70%.23–25
The pathophysiology of sepsis-induced cardiac dysfunction is suggested to be functional,
and not due to physical structural changes. Previous studies showed that dysfunction may
be reversible in 7-10 days.26 There are two phases of septic shock that are characterized by
different parameters of myocardial dysfunction. The early “warm” phase is hyperdynamic
shock. It is comprised of high cardiac output, low peripheral vascular resistance, and
increased temperature in the extremities of the body. This is followed by the late “cold”
phase of hypodynamic shock, which is indicated by hypotension, low cardiac output, poor
peripheral perfusion, and cold extremities. The latter phase may be followed by death.27,28

1.2.1 Proinflammatory cytokine and cardiac dysfunction
The detrimental effect of LPS on cardiac function is mediated through the production of
proinflammatory cytokines.29 LPS-stimulated proinflammatory cytokines, particularly
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tumor necrosis factor (TNF)-α and interleukin 6 (IL-6), have been suggested to be main
components in cardiac dysfunction.25 Patients with sepsis often have impaired cardiac
function as a consequence of elevated proinflammatory cytokine levels.30 As well, the LPSactivated TLR4 pathway has a direct role in cardiac dysfunction in sepsis. Previous studies
showed that TLR4 knockout mice have reduced cardiac depression and lower myocardial
proinflammatory cytokine expression when challenged with LPS injection compared to
wild-type mice.31 This suggests that LPS binding to TLR4 in cardiomyocytes resulting in
downstream activation of NF-κB and proinflammatory cytokine release during
endotoxemia regulates cardiac depression.
Similarly, TNF-α administration has been shown to induce symptoms similar to sepsis with
multi-organ failure, including hypotension, pulmonary and gastrointestinal hemorrhage,
tubular necrosis and death.32 High levels of TNF-α produced in the myocardium contribute
to the development of cardiac dysfunction.33 The high cytokine levels depress cardiac
contractile function in live animals and isolated cardiomyocytes.34,35 LPS-induced
myocardial dysfunction is abrogated by treatment with TNF-α antiserum, and
administration of TNF-α binding proteins preserve myocardial function in mice in
endotoxemia.33,34 Thus, TNF-α activity plays an important role in LPS-induced myocardial
dysfunction.

1.2.2 Cardiomyocytes in sepsis
Cardiomyocytes account for about 70% of the mammalian heart mass.36 The severity of
sepsis-induced cardiac dysfunction is a prognostic factor of sepsis. As such, one strategy
in combating sepsis is the prevention of cardiomyocyte damage.
Previous studies showed that cardiomyocytes produce and secrete proinflammatory
cytokines after LPS treatment in both mice and humans.33,37 As well, LPS binding to TLR4
induced inflammation in stem-cell derived cardiomyocytes in vitro.37 In HL-1 cardiac
muscle cells, troponin I expression was enhanced when treated with LPS.38 Additionally,
LPS stimulation resulted in higher troponin levels in both HL-1 and human cardiomyocyte
supernatant.38 Troponin I is a marker of myocardial injury and may indicate myocardial
involvement in sepsis.24 Elevated levels of cardiac troponin I are detected in patients with
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severe sepsis and septic shock.39 Furthermore, release of cardiac troponin I during sepsis
is a predictor of mortality in septic patients, and may be dependent on cytokine levels or
caused by myocardial membrane leakage.40,41 Thus, cardiomyocytes are involved in sepsis
pathogenesis.

Toll-like receptors (TLRs)
Toll-like receptors (TLRs) are a family of protein receptors that can recognize a variety of
pathogen associated molecular patterns (PAMPs). As such, they are important for innate
immune responses. TLRs dimerize and are activated by PAMPs, resulting in downstream
signaling to initiate innate immune response.42 All TLRs share a conserved N-terminal
extracellular region composed of leucine-rich-repeat (LRR) domains and a C-terminal
cytoplasmic region.42 The LRR domains are essential for pathogen recognition through
protein-protein interactions.43 In humans, TLR1-10 are found, and among these TLR2,
TLR3, TLR4, TLR5, and TLR9 have been shown to be involved in recognizing microbial
pathogens.44 Of interest to the present study, TLR4 mainly recognizes LPS and has a role
in the release of proinflammatory cytokines, which may lead to sepsis.45

1.3.1 Toll-like receptor 4 (TLR4)
TLR4 is primarily found in cells of myeloid origin (e.g. macrophages, dendritic cells), but
it is also expressed in cardiomyocytes and endothelial cells.46–48 TLR4 signaling has a
central role in the innate immune response. LPS activates TLR4 to stimulate inflammatory
cytokine release and innate immune responses, which is the immediate host defense against
microbial pathogens.49 Thus, TLR4 signaling pathway has an important role of the in the
pathogenesis of sepsis.
LPS does not directly bind to TLR4. Rather, it binds to LPS-binding protein (LBP), which
is a phospholipid transport protein that facilitates LPS binding to cluster of differentiation
14 (CD-14), a membrane glycoprotein.49 With the additional interaction with lymphocyte
antigen 96, also known as MD-2, which recognizes and binds the lipophilic domain of LPS
(lipid A), this complex promotes TLR4 to dimerize and induce downstream signaling.
Activated TLR4 can either recruit myeloid differentiation factor (MyD) 88 or become
internalized into endosomes and interact with TIR-domain-containing adapter-inducing
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interferon-β (TRIF). Both pathways are mutually exclusive.50 The MyD88-dependent
pathway results in the activation of nuclear factor kappa-light-chain-enhancer of activated
B cells (NF-κB) and production of proinflammatory cytokines, such as IL-6, IL-1β, and
TNF-α, whereas the TRIF-dependent pathway results in the slower activation of NF-κB
and the transcription of the interferon (IFN)-β gene.49,51
The association of MyD88 to TLR4 further recruits interleulin-1 receptor-associated
protein kinases (IRAKs). This triggers downstream signaling pathways including Rac1 and
NADPH oxidase. Additionally, recruited IRAKs activate downstream TNFR-associated
factor 6 (TRAF6), leading to the subsequent activation of transforming growth factor-βactivated kinase 1 (TAK1). This leads to the activation of transcription factors such as NFκB and the production of proinflammatory cytokines.19 As well, a parallel downstream
pathway of MyD88 is the simultaneous activation of mitogen-activated protein kinases
(MAPKs), which leads to further activation of inflammatory cytokines (Figure 1.1).52
Activation of TLR4 by LPS result in the release of inflammatory cytokines, and TNF-a is
released within 30–90 min after LPS stimulation.53 Subsequently, activation of
inflammatory cascades and upregulation of adhesion molecules result in inflammatory cell
migration into tissues.53 Additionally, excessive release of proinflammatory mediators
stimulate the production of reactive oxygen species and nitric oxide, resulting in tissue
damage and inducing further inflammatory response.54 Damaged tissues will produce
endogenous damage-associated molecular patterns (DAMPs), which will activate TLRs
and exacerbate the immune response. Finally, this inflammatory cycle may cause organ
failure, cardiac dysfunction, and eventually death.27 Inhibition of TLR4 was shown to
alleviate the detrimental effects of LPS.55 Similarly, blocking LPS-TLR4 association is
protective against endotoxic shock in humans.56 In clinical settings, modeling TLR4
expression allowed an accurate characterization of the clinical outcomes of sepsis
patients.57 Thus, overactivation of TLR4 by LPS contributes to the pathogenesis of sepsis.
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Figure 1.1. LPS stimulation of TLR4 leads to proinflammatory cytokine release. 1.
LPS interacts with LBP, which facilitates binding to glycoprotein CD14. This binding
structure interacts with MD-2 to bind to TLR4. TLR4 dimerizes upon LPS activation of
the receptor. 2. TLR4 activation recruits MyD88. This interaction further recruits IRAK1
and IRAK6. This complex activates further downstream signaling pathways. 3a. NF-κB is
activated following IκB phosphorylation. 3b. MAPKs JNK1, p38, and ERK1/2 are
activated by MKKs, causing nuclear translocation of AP-1. 4. As a result of TLR4
activation, there is increased release of proinflammatory cytokines which leads to
inflammation, cardiac dysfunction, and eventually death.
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Mitogen-activated protein kinases in sepsis
Mitogen-activated protein kinases (MAPKs) are a group of serine/threonine protein kinases
with three well-delineated subfamilies, including extracellular-signal-regulated kinase
(ERK) 1/2, the c-Jun NH2- terminal kinases (JNK) and p38 kinases. MAPK pathway
signaling is induced by upstream receptor activation, including GPCR and TLR4. MAPKs’
activities are regulated by their phosphorylation levels. Each MAPK can be phosphorylated
by upstream kinases including mitogen-activated protein kinase kinase (MKKs), as well as
PKA and PKC.58 Upstream activity of MAP kinase kinase kinase (MAP3K) activates MKK
in a sequential phosphorylation cascade to trigger MAPK signaling.59 Regulation of
substrates downstream of MAPK activity modulates cellular pathways in proliferation,
differentiation, inflammation, and apoptosis.55 Inactivation of MAPK signaling is mediated
by MAPK phosphatases (MKPs), which dephosphorylate both the threonine and tyrosine
residues.60
MAPKs are mediators in LPS-induced TNF-α production (Figure 1.1).26,61,62 Activation of
MAPKs and Akt in the heart during sepsis causes cardiac dysfunction in mice.63 In the
latter study, left ventricular cardiomyocytes and macrophages showed activation of
MAPKs under septic conditions. Our lab previously elucidated specific roles for MAPKs
in the regulation of myocardial TNF-α expression during sepsis, showing that gp91phoxcontaining nicotinamide adenine dinucleotide phosphate (NADPH) oxidase signaling
contributes to LPS-stimulated TNF-α expression in cardiomyocytes.64,65 This effect was
facilitated through p38 and ERK1/2 MAPK signaling pathways.65 ERK has two
ubiquitously expressed isoforms, ERK1/2, and is involved in regulation of inflammatory
cytokine synthesis.66 The p38 MAPK α isoform is targeted by endotoxins in mammalian
cells.67 It has a regulatory role in inflammatory cytokine release via both transcriptional
and post-transcriptional mechanisms.68 p38 MAPK activity is also regulated by Gαsinduced cAMP signaling pathways and Gq-PLCβ pathways.69,70
LPS can also induce myocardial MKP1 expression via JNK1. MKP1 attenuates ERK1/2
and p38 activation, which inhibits myocardial TNF-α expression during endotoxemia.71
ERK1/2 and JNK are important in many cellular pathways; ERK1/2 activity can be
modulated by upstream G protein signaling, and JNK activation can be activated by Gi-
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and Gq-stimulated pathways and supressed by cAMP signaling.70,72 As c-Jun is a part of
the activator protein-1 transcription factor (AP-1), which regulates the expression of
proinflammatory cytokines, JNK is involved in inflammatory response pathways.73
Increased expression of JNK/c-fos resulted in lower phosphorylation of ERK1/2 and p38,
which leads to lower TNF-α expression in LPS-stimulated cardiomyocytes.61

NF-B in inflammatory signaling
The nuclear factor of kappa light polypeptide gene enhancer in B-cells (NF-κB) is an
inducible transcription factor that plays a central role in physiological and pathological
conditions.74 While it exhibits a constitutive background activity, the pathway is inducible
by factors including cytokines, toll-like receptor ligands, and bacteria. The NF-κB family
consists of members that form dimeric transcription factors, and these bind to specific DNA
targets known as κB binding sites. κB binding sites are present in promoter and enhancer
regions of a multitude of genes.75 When inactive, NF-κB is found in the cytoplasm bound
and inhibited by nuclear factor of kappa light polypeptide gene enhancer in B-cells
inhibitor (IκB) proteins, which masks the nuclear translocation sequence. When induced,
the canonical activation of NF-κB involves the phosphorylation of IκBα by IκB kinases
(IKK), leading to its degradation.76,77 IKK activity can be triggered by cytokines, mitogens,
stress factors, and microbial components.78 Following IκBα degradation, NF-κB members,
mainly p50/p65 dimers, translocate to the nucleus.76 Activation of NF-κB increases the
presence of nuclear DNA-binding subunits, which bind to specific κB binding sites to
regulate the expression of target genes.
This canonical pathway of NF-κB activation is responsible for TLR-mediated expression
of inflammatory cytokines such as TNF-α and IL-6.75 TLR4 activation can induce NF-κB
activity through two signaling pathways (Figure 1.1). Briefly, through activation of
interleukin-1 receptor associated kinases (IRAKs) and recruitment of transforming growth
factor--activated kinase-1 (TAK1), MyD88 can mediate the activation of the IKK
complex as well as MAPKs. In MyD88 deficient mice and cells, TLR activation is able to
induce neither NF-κB activity nor inflammatory cytokine expression in response to LPS.79
In addition, TLR4 induces NF-κB activity through a TRIF-dependent pathway, resulting
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in a corresponding expression of inflammatory cytokines. This pathway converges with
the MyD88-dependent path through a similar activation of TAK1.75 TAK1 deficient cells
have lower levels of NF-κB and MAPK activity, resulting in impaired inflammatory
response.80 Similarly, in TRIF-deficient cells, early LPS activation of NF-κB is still
present.81 In contrast, when both MyD88 and TRIF are knocked out, there is a complete
absence of NF-κB activity when stimulated by LPS.81 Thus, TLR4 mediated inflammatory
response through the activation of NF-κB is reliant on both the MyD88 and TRIF pathways.
NF-κB is a central mediator of proinflammatory cytokine expression and can prolong
inflammatory conditions through a feed-forward loop via IKK activity.77,82 IKK
phosphorylates IκB proteins to activate the NF-κB transcription factors. A substrate of IKK
is the E3 ubiquitin ligase Itchy homolog, ITCH, which is involved in the suppression of
TNF-mediated NF-κB activation. ITCH activity is impaired when it is phosphorylated by
IKK, which prolongs NF-κB signaling and proinflammatory cytokine release, such as
TNF-α.82

G protein-coupled receptors
G protein-coupled receptors (GPCRs), which have seven transmembrane domains, are the
largest membrane receptor family. They are involved in diverse physiological and disease
processes. GPCRs transduce signals from a multitude of molecules including hormones,
neurotransmitters, chemokines, and autocrine and paracrine factors.83
Signal transduction in mammalian cells is regulated by mechanisms that amplify or
attenuate agonist-initiated biochemical cascades.84 As shown in Figure 1.2, the Gα-subunit
in the inactivated state typically is found bound to guanosine diphosphate (GDP). When a
GPCR is activated by a ligand, GDP is exchanged for guanosine triphosphate (GTP) on the
receptor-associated Gα-subunit. This results in a conformational rearrangement and likely
the dissociation of Gβγ-subunit from the Gα-subunit. Both subunits can activate
downstream messenger cascades. Eventually, the intrinsic GTPase activity of the Gαsubunit catalyzes the hydrolysis of GTP to GDP. The inactive heterotrimeric G protein
complex then re-forms, and G protein signaling is abrogated.85
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Figure 1.2. Conventional signaling pathways of Gαs and Gαq activity. Upon activation,
Gαq stimulates phospholipase Cβ (PLCβ) to cleave PIP2 to the second messengers inositol
trisphosphate (IP3) and diacylglycerol (DAG). IP3 increases intracellular Ca2+
concentration by inducing Ca2+ release from the endoplasmic reticulum. DAG activates
protein kinase C (PKC). Gαs stimulates adenylyl cyclase (AC) to produce the second
messenger cAMP, which activates protein kinase A (PKA). This results in the
phosphorylation of many intracellular proteins and affects many intracellular pathways.
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G proteins can be sorted into four classes depending on their Gα-subunits: Gα stimulatory
(Gαs), Gα inhibitory (Gαi), Gαq and Gα12/13.86 The different classes and subunits, when
activated, trigger a variety of distinct pathways. As shown in Figure 1.2, activated Gαs
stimulates adenylyl cyclase to produce the second messenger cyclic adenosine
monophosphate (cAMP), which in turn activates protein kinase A (PKA) as well as
exchange protein directly activated by cAMP (EPAC) and cyclic nucleotide-gated ion
channels such as hyperpolarization-activated cyclic nucleotide-gated (HCN) channels in
cardiac pacemaker cells.87 When activated, PKA is able to phosphorylate other intracellular
proteins and affect many intracellular pathways. Opposing the actions of Gαs, Gαi inhibits
adenylyl cyclase activity to limit the production of cAMP.88 Gαq stimulates phospholipase
Cβ (PLCβ) as well as the small G protein nucleotide exchange factor p63RhoGEF.89
Activated PLC cleaves phosphatidylinositol 4,5‐bisphosphate (PIP2) to yield the second
messengers inositol 1,4,5‐triphosphate (IP3) and diacylglycerol (DAG). IP3 increases
Ca2+ release from the endoplasmic reticulum, and thus enhances Ca2+ concentration. DAG
and IP3 can activate protein kinase C (PKC), either directly or indirectly via the release of
Ca2+, respectively.70,83 This results in downstream phosphorylation of proteins to modulate
intracellular pathways.88

1.6.1 G-protein signaling regulates MAPK activity
When activated, G proteins regulate signal transduction via mechanisms that intensify or
mitigate cellular pathways, including the activation of MAPKs via activation of small, Raslike G proteins, modulation of the MAPK phosphorylation cascade or transactivation of
receptor tyrosine kinases.70,84 Gαs stimulates ERK1/2 and p38 signaling via its activation
of cAMP production. Specifically, cAMP activation of EPAC stimulates Rap-1 signaling,
which is capable of inducing b-Raf, a MAP3K, upstream of ERK1/2.90,91 However, the
EPAC-dependent activation of ERK1/2 via Rap-1 is cell specific.92 cAMP-mediated PKA
activity is also involved as an upstream regulator of ERK1/2 via Rap-1. PKA-mediated
upstream regulation of ERK1/2 is cell type dependent and can amplify and/or attenuate the
MAPK activity. For example, PKA is involved in agonist-stimulated ERK1/2 activation
via Ras in human embryonic kidney cells, while in arterial smooth muscle cells, PKA
inhibited the upstream signaling of MKK.93,94 In cardiomyocytes, PKA can also target
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Ca2+-handling proteins.95 Similar to the Gαs induced ERK1/2 MAPK, β2-AR activation
mediated the Gαs-cAMP–PKA stimulation of p38 signaling in cardiomyocytes.96 Gi
mediates MAPK activity through its α-subunit as well as βγ-subunit.70 In fibroblast cells,
Gαi can activate ERK1/2 signaling through direct or indirect stimulation of Ras. 97 Gαi is
known to inhibit AC activity, reducing cAMP levels. This decrease alleviates the inhibitory
effect of PKA on upstream c-Raf, which enhances ERK1/2 signaling.70 Gαi also activates
ERK1/2 and JNK directly through βγ-subunit dependent mechanism and indirectly via
PI3K activity.98
Finally, Gαq mediates MAPK signaling via activation of PLCβ.70 The effector PLCβ can
be activated by the Gαq-subunit, and the βγ-subunit can enhance the effect of the Gαqsubunit.99 Upon activation, PLCβ activates PKC and increases intracellular Ca2+ levels,
both which induces ERK1/2, JNK, and p38 MAPK signaling.70 Gαq stimulated PKC can
phosphorylate c-Raf, upstream of ERK1/2. Additionally, Gαq can induce ERK1/2 via a
Ca2+-calmodulin mediated pathway, while both DAG and Ca2+ can activate Rap-1 to
enhance ERK1/2 activity.100 Lastly, Gαq mediates p38 activity through PKC signaling or
βγ-subunit activated Rap-1 pathways.101 Thus, GPCR activity may be involved in the
inflammatory response in sepsis via the MAPK pathways.

1.6.2 G protein signaling in sepsis
Cardiovascular function including cardiac contractility, heart rate and vascular tone, etc. is
regulated by GPCR signaling. The receptor family can be found in different cells involved
in the cardiovascular system, including cardiomyocytes, fibroblasts, and endothelial cells.
As such, GPCRs are widely used therapeutic targets for pharmacological treatment
including angiotensin converting enzyme (ACE) inhibitors, and β-AR ligands.102 For
example, dobutamine is a selective adrenergic receptor agonist and an inotropic agent for
the treatment of cardiogenic shock.103
The initial phase of sepsis is identified by increased catecholamine levels as a part of the
compensatory adrenergic response to alleviate myocardial depression.104 In the long term
however, this excessive stimulation of cardiac β-AR and intracellular Ca2+ levels may be
detrimental for the heart, resulting in myocardial damage, cardiac dysfunction, tachycardia,
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and apoptosis.105 β2-AR can also stimulate Ca2+ release from intracellular stores via PLC
and opening of IP3 receptors, which does not involve the canonical β2-AR-GPCR signaling
pathways.106Additionally, desensitization and downregulation of β-AR is associated with
sepsis progression, which may be cause by prolonged cytokine expression.107 Chronic
elevations of catecholamines an also activate α1-AR in the heart, which contributes to
contractility via Gαq signaling.108 In contrast to the downregulation of β-AR, α1-AR
activity is maintained during heart failure.109,110
Adenylyl cyclase (AC) activity is reduced in the late hypodynamic stage of sepsis, thought
this may be isoform dependent as AC4 expression was enhanced in the heart.111,112
Enhanced phosphodiesterase (PDE) activity during sepsis may also contribute to the
desensitization of β-AR stimulation. Dobutamine’s inotropic effect was impaired in
sepsis.113 While surface expression levels of β1-adrenoceptors and α-subunits of three main
G protein families in the myocardium were not different from control, plasma cAMP levels
were lower as a result of upregulated PDE4D expression.113 Endotoxemia can also induce
a systemic downregulation of α1-AR expression, which may contribute to circulatory
failure in sepsis.114 Similarly, Gαs induced production of mitochondrial cAMP was
impaired in the myocardium in sepsis.115
Gαi signaling may also contribute to negative inotropic effect of LPS in cardiomyocytes.116
As well, adrenergic receptors modulate inflammation and the immune response.
Stimulation of α2-adrenoceptor in vivo resulted in higher proinflammatory cytokines
release, including TNF-α.117,118 In contrast, treatment of dexmedetomidine, an α2adrenoceptor agonist, alleviated septic renal dysfunction and lowered the expression of
proinflammatory cytokines (e.g. TNF-α).119 However, this effect may be due to the renal
specific and initial effects of the drug, which reduces the sympathetic response and
catecholamine release, alleviating inflammation.119,120 Currently, norepinephrine, which
targets adrenergic receptors, is the first-line recommendation for treatment of septic
shock.12 Thus, G protein signaling is involved in septic conditions.
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Regulators of G protein signaling
Regulator of G protein signaling (RGS) are expressed in many tissues and are involved in
diverse physiological and disease processes. They function as GTPase-activating proteins
(GAPs) for G protein α-subunit through a conserved ~120 amino acid RGS domain.121,122
As GAPs, RGS proteins increase the rate of hydrolysis of the Gα-subunit-bound GTP,
inhibiting downstream signaling pathways. As well, at least some RGS proteins can act
through GAP-independent mechanisms to limit GPCR signaling. For example, RGS2 not
only promotes Gαs GTPase activity but also acts as an “effector antagonist” by binding to
Gαs and/or AC to limit GPCR-stimulated cAMP production, as well as Gαq-mediated
PLCβ activation (Figure 1.3).123–126 Thus, RGS limits GPCR signaling through both GAPdependent and -independent mechanisms.
In mammals, there are currently twenty identified RGS genes and some of these encode
multiple splice variants. These proteins and their splice variants can be further categorized
into four subfamilies: R4/B, RZ/A, R7/C, and R12/D.124 The predominant RGS proteins
expressed in the cardiovascular system are the small RGS R4/B subfamily members,
RGS2-5.127 Additionally, R7/C subfamily member RGS6 is also found in the ventricles
and is considered to be cardioprotective.128 These RGS proteins are prevalent in
mammalian hearts and expressed in cardiomyocytes and fibroblasts.129–131 RGS2-4 have
altered expression profiles in human heart failure.130,132 In the heart, RGS4 and RGS5 are
predominantly expressed in the atria, while RGS2 is highly expressed in the
ventricles.127,129 Thus, targeting RGS2 therapeutically has the potential to be clinically
beneficial.133,134
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Figure 1.3. RGS2 regulation of G protein signaling . Under basal conditions, Gα has a
GDP bound to it. Upon activation of the GPCR, GDP-GTP exchange on Gα is thought to
cause the separation of Gα from Gβγ, allowing receptor-mediated activity and initiating
downstream signaling cascades. RGS2 increases the intrinsic GTP hydrolytic activity of
Gα. This GAP effect attenuates Gα activity and results in a return to the ground state of the
heterotrimeric G protein subunits. This also stops Gβγ signaling activity. As well, RGS2
can act through GAP-independent activity as an effector antagonist binding adenylyl
cyclase (AC) and Gαs-mediated cAMP production, as well as Gαq-mediated phospholipase
Cβ signaling.
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1.7.1 Regulator of G protein signaling 2
In addition to being expressed in the heart, RGS2 is detected throughout the body,
including the brain, vasculature, and kidneys. As part of the R4/B subfamily, it has a
relatively small and simple structure. It preferentially targets Gαq- and Gαs-mediated
pathways which are implicated in blood pressure regulation and cardiac hypertrophy.135,136
RGS2 is unique in its relatively low affinity for Gαi/o proteins, due to its conformation
and/or sequence in its binding pocket.137 GPCRs can also recruit RGS2 to the plasma
membrane without the requirement of receptor activation.138 The region between the RGS
domain and the N-terminus has been shown to selectively target the M1 muscarinic
acetylcholine receptor, α1A and β2-adrenergic receptors.123,139,140 Previous studies also
identified a 37 amino acid binding domain (RGS2eb) within the RGS2 domain that binds
eIF2Bε, which inhibits global protein synthesis.141,142 Additionally, a point mutation in
RGS2 inhibited its GAP activity but did not affect RGS2 translational control. This shows
that the mechanism by which RGS2 is able to reduce protein synthesis is also independent
of its modulation of GPCR activity.142
RGS2 activity can be modulated by phosphorylation, which is facilitated by PKC and type
I α cGMP-dependent protein kinase (cGKIα), to

increase RGS2’s GAP-dependent

activity.143,144 As well, proteolytic degradation of RGS2 affects its downstream inhibition
of GPCR signaling.145 Inhibition of cGK activity limits RGS2 degradation.144 RGS2 also
attenuates Gαq-coupled vasoconstriction in vascular smooth muscle.146 Gαq has been
shown to be involved in myocardial hypertrophy – Gαq-coupled receptors exert diverse
effects on myocyte growth, contractility, and heart rate.147 In addition, Gαq contributes
significantly to the maladaptive remodeling that results from pressure overload.148
Finally, RGS2 deficient mice exhibit a strong hypertensive phenotype, renovascular
abnormalities, and prolonged response to vasoconstrictors in vivo.149 These mice are more
likely to have atrial fibrillation caused by increased M3 muscarinic receptor activity, which
is associated with increases in higher vagal tone and is predominantly coupled to Gαq class
of G proteins.150,151 Additionally, RGS2 deficiency resulted in a hypertensive mice, and
pressure overload leads to hypertrophy, heart failure, and death.136,149,152 Clinical cases of
hypertensive patients have decreased RGS2 mRNA and protein levels.132,153 In contrast,
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hypotension is a symptom of Bartter's/Gitelman's syndrome, in which patients have
increased RGS2 expression.154
RGS2 expression is also altered in cardiovascular disease models. For example, RGS2 is
downregulated in cardiac hypertrophy and heart failure models. As well, there is an acute
enhancement of its expression in response to GPCR agonists that promote hypertrophy in
cardiomyocytes.135,155,156 Correspondingly, sustaining RGS2 expression improves cardiac
hypertrophy in vitro and in vivo.134,157 By upregulating RGS2 protein levels, digoxin was
cardioprotective against cardiac hypertrophy and injury in vivo; this effect was absent in
RGS2 deficient mice.157 Similarly, lower levels of RGS2 and higher angiotensin II
mediated MAPK activity was detected in hypertensive patient samples of human skin
fibroblasts and peripheral blood mononuclear cells.158 Thus, RGS2 has a regulatory role in
the heart and is a pharmacological target in the treatment of cardiovascular diseases.157
Currently, its role in sepsis is unclear.

Summary and rationale
While both the LPS-stimulated TLR4 and the RGS2-regulated GPCR pathways are well
established, no studies to date have investigated how these two interact in the heart. RGS2
has been suggested to inhibit MAPKs, including p38, ERK1/2, and JNK (Figure 1.4).62
Notably, these mediators have been implicated in proinflammatory cytokine release in
endotoxemia. Crosstalk among JNK, p38 and ERK is another important feature in MAPK
signaling. JNK1 suppresses TNF-α expression in LPS-stimulated cardiomyocytes.61
Inhibition of TNF-α expression by JNK1 signaling is mediated by c-fos induction and
down-regulation of ERK and p38 phosphorylation. This negative crosstalk between JNK1
and ERK/p38 signaling may limit TNF-α expression in sepsis. Furthermore, it has been
demonstrated that inhibition of p38 activation decreases TNF-α expression in the heart and
improves cardiac function and survival during endotoxemia.33 This also suggests an
important role for p38 in the development of cardiac dysfunction in sepsis. Thus, RGS2
may be able to regulate the release of proinflammatory cytokines through modulating
MAPK phosphorylation.
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Induced activation of NF-κB may be downstream of MAPK signaling. Additionally, NFκB was shown to be involve in a feedforward loop that exacerbate inflammatory conditions
(Figure 1.4).82 TLR4 activation induces further downstream IKK complex activity.42 RGS2
may further modulate kinase activity by limiting the downstream activity of PKC.159
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Figure 1.4. Possible crosstalk mechanisms involving the role of RGS2 in limiting G
protein signaling activity. 1. RGS2 may inhibit LPS-induced expression through
downregulation of mitogen-activated protein kinases (MAPKs) p38, ERK1/2, and JNK,
which are implicated in proinflammatory cytokine release in endotoxemia. 2. TLR4
regulates downstream IKK complex activity. RGS2 may further modulate kinase activity
by downstream regulation by protein kinase C. All signaling pathways result in the
production of proinflammatory cytokines, leading to inflammation and cardiac
dysfunction.
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Hypothesis and aims
This study investigated how global RGS2 deficiency affects inflammatory cytokine release
within the heart and elucidated its mechanism of action during endotoxemia.
We hypothesized that RGS2 deficiency would enhance the proinflammatory response in
endotoxemia.

The specific objectives of the study were:
1) To determine the role of RGS2 in LPS-induced inflammatory cytokine (e.g. TNF-α)
release in the heart.
Adult male wild-type (WT) and RGS2-/- C57BL/6 mice were used as our control and RGS2
deficient models, respectively, which have been used in previously in our lab.151,160,161
These mice were treated with LPS (4 mg/kg) by intraperitoneal (IP) injection; previous
studies showed that the dosage is sufficient to induce endotoxemia to model septic
conditions.61
While the in vivo model allowed us to understand the physiological relevance of RGS2,
studying molecular and cellular mechanisms required isolated cells, which avoided the
complexity of whole animal studies. Thus, we complemented our in vivo model with an in
vitro primary neonatal mouse cardiomyocyte model. This isolated model allowed studying
the specific role of RGS2 in cardiomyocytes in septic conditions.
To determine the physiological role of RGS2 in inflammatory cytokine release under
endotoxemic conditions, inflammatory cytokine levels, including TNF-α, IL-6, and IL-1β
were assessed. As well, we detected altered cardiac function using echocardiography.
2) To identify specific pathways regulated by RGS2.
To determine specific mechanism through which RGS2 affects during endotoxemia, we
detected the phosphorylation of pathway mediators by immunoblotting. These included
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ERK1/2 and p38 MAPKs. Relative NF-κB activity was detected via ELISA. Finally, the
signaling mediator PKA was inhibited using a selective inhibitor H89 and changes in LPSinduced inflammatory response were assessed.
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Chapter 2

2

Materials and Methods
In vivo C57BL/6 mouse model

This study utilized mice in accordance with the Guidelines for the Care and Use of Animals
by the Canadian Council of Animal Care. The study protocol was approved by the Animal
Care Committee at Western University, Canada (AUP #2016-099, Appendix A). Wildtype (WT) C57BL/6 mice were purchased from Jackson Laboratory (Bar Harbor, Maine).
Generation of RGS2-/- mice have been previously described.162,163 Mice were given water
and chow ad libitum and held on a 12h-12h light-dark cycle. All mice used were 3-5 months
old males. Female mice were not used in the present experiment to avoid sex-dependent
differences in the inflammatory response during endotoxemia, which may be affected by
the estrous cycle.164,165

2.1.1 LPS-induced endotoxemia mouse model
WT and RGS2-/- mice were treated with saline as control or 4 mg/kg LPS by intraperitoneal
(IP) injection to induce endotoxemia. Plasma and left ventricular tissues were collected
0.5, 2, 4, or 24 hours after injection. LPS treatment periods were previously established in
our lab.61,71 Blood was collected by cardiac puncture in heparinized needles and tubes.
Plasma was isolated from blood by centrifugation at 5,000 x g for 5 minutes at 4 °C, and
the top layer of plasma was transferred to a new tube. The left ventricle (LV) of the heart
was isolated and collected. All samples were stored at -80 °C until analysed.

Primary neonatal cardiomyocyte cell culture
2.2.1 Isolation of neonatal cardiomyocytes
Primary cultures of neonatal mouse cardiomyocytes were used according to methods
previously described, with minor adjustments.160,166,167 Male and female WT and RGS2-/neonates (P0) were sacrificed and sterilized rapidly in clinicide (Vetoquinol, Lavaltrie,
Québec). Using sterilized tools, neonatal ventricles were collected and washed in D-Hanks
solution (H2389, Sigma, St. Louis, Missouri). Ventricles were cut into 4-6 pieces/heart and
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incubated in neonatal heart digestion buffer (Liberase TH, Roche; 22.5 µg/mL in D-Hanks
solution) at 37 °C for 15 minutes. Digestion buffer for the first digestion incubation was
removed, and fresh digestion buffer was added. Ventricles were incubated for 15 minutes
with occasional gentle shaking. Digested ventricles were then broken down mechanically
by thorough triturating of the tissue to release cells. The supernatant, which contained cells,
was transferred to a new tube and centrifuged at 180 x g for 4 minutes at room temperature.
Cells were re-suspended in neonatal cardiomyocyte culture media (M199 media, 10% fetal
bovine serum FBS, 1% penicillin/streptomycin, 1% L-glutamine) and pre-plated on a
sterilized cell culture dish. Fresh digestion buffer was added to the ventricles and digestion
was repeated two more times, for a total of four digestion incubations (1 hour total). After
the final digestion, pre-plated cells were incubated for 45 minutes to allow fibroblasts to
strongly adhere to the bottom of the plate.
Weakly adhered cardiomyocytes were then gently washed off the dish and isolated from
the adhered fibroblasts, filtered via gravity to remove any large tissue debris, and resuspended in neonatal cardiomyocyte culture media. Neonatal cardiomyocytes were
seeded on 1% gelatin coated plates. Neonatal cardiomyocytes were incubated at 37 °C with
5% CO2 for 48 hours prior to treatment. Overall health of neonatal cardiomyocytes was
confirmed via microscopy to detect overall abundance of cells and cardiomyocyte
contraction. Quality of cultured cardiomyocytes was confirmed by immunohistochemistry.

2.2.2 LPS-induced inflammatory cytokine release in cardiomyocytes
Neonatal cardiomyocyte cultures were washed briefly with sterile phosphate buffered
saline (PBS), and fresh cardiomyocyte culture medium was added. Cells were treated with
medium as control, and LPS (5 µg/mL) for 0.5, 2, and 4 hours at 37 °C with 5 % CO2. LPS
treatment periods were previously established.61,71 At the end of the treatment period,
media and cardiomyocyte cells were collected and stored at -80 °C.

2.2.3 PKA inhibition in LPS-induced inflammatory cytokine release
PKA inhibitor H89 was used to pre-treat cardiomyocyte cultures prior to LPS treatment.
After the 48 hours incubation period, cardiomyocyte cultures were washed with PBS. H89
was added to achieve 20 µM in cardiomyocyte culture medium for 30 minutes of pre-
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treatment. DMSO was used as control. After pre-treatment, LPS (5 µg/mL) was added
directly to the cardiomyocyte culture media for 2 and 4 hours at 37 °C with 5% CO2. Media
and cardiomyocyte cells were collected and stored at -80 °C.

2.2.4 Immunohistochemistry of cardiomyocytes
Cultured neonatal cardiomyocyte cells were seeded on 1% laminin-coated glass slide after
the pre-plating period. Cells were incubated at 37 °C with 5% CO2 for 48 hours. Prior to
fixation, cells were washed with PBS. Cardiomyocytes were fixed with cold 100%
methanol for 15 minutes at 4 °C, then briefly washed with PBS.
Purity of the cardiomyocyte culture was confirmed by α-actinin staining to identify cells
that were cardiomyocytes. Fixed cells were blocked for 1 hour at room temperature in goat
serum, then incubated in primary α-actinin antibody (1:1,000; #A7811, Sigma, St. Louis,
MO) overnight at room temperature in a humidity chamber. Cells were washed with PBS,
then incubated in secondary antibody (1:1,000 Cy3-conjugated goat anti-mouse IgG;
Jackson ImmunoResearch, PA) for 1 hr. Cells were briefly washed with PBS, then nuclei
were stained using Hoechst 33342 stain (1:1,000 Invitrogen, Carlsbad, CA) for 10 minutes.
A glass coverslip was mounted on the slide, and the cells were imaged using fluorescence
microscopy (Figure 2.1).

26

Figure 2.1: Efficacy of the isolation of neonatal cardiomyocytes. Representative
fluorescent image of fixed WT (A) and RGS2-/- (B) mouse primary neonatal
cardiomyocytes stained for α-actinin (red) and Hoechst stain (blue) for detection of the
nucleus. Scale bar (white) = 20 µm. More than 90% of stained cells were identified as
cardiomyocytes.

Quantitative polymerase chain reaction
2.3.1 RNA isolation from LV tissues
RNA was collected from tissue samples using TRIzol reagent (Invitrogen). Briefly, left
ventricle samples collected from WT and RGS2-/- mice treated with LPS (4 mg/kg) or saline
for 2 hours treated were washed in ice cold PBS, then mechanically homogenized using a
Model PRO 200 (PRO Scientific Inc., Monroe, CT USA) in 500 µL/sample TRIzol.
Chloroform was added (1/5 of TRIzol volume; 100 µL/sample) and samples were vortexed
vigorously. After 10 minutes at room temperature, the samples were centrifuged at 12,000
x g at 4 °C for 15 minutes. The aqueous top layer containing the RNA was transferred to a
new tube, and isopropanol was added (1/2 of TRIzol volume; 250 µL/sample). Samples
were briefly vortexed, then incubated at room temperature for 10 minutes. The sample was
centrifuged at 12,000 x g at 4 °C for 10 minutes to pellet the precipitated RNA. The
supernatant was removed, and the RNA pellet was washed superficially using 75% ethanol
in 0.1% DEPC water (same as TRIzol volume; 500 µL/sample). The sample was again
centrifuged at 12,000 x g at 4 °C for 10 minutes. Ethanol wash was removed, and RNA
pellet was air dried until no liquid remained (about 30 minutes). The RNA pellet was
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resuspended in 0.1% DEPC water, then heated to 65 °C for 10 minutes. RNA quality and
quantity were assessed using the NanodropLite spectrophotometer (Thermo Fisher
Scientific, Waltham, Massachusetts).

2.3.2 RNA isolation from cardiomyocytes
Cardiomyocyte cells treated with LPS for 2 hours were washed with ice cold PBS, and then
lysed using TRIzol reagent (500 µL/sample) on ice. RNA was isolated using the TRIzol
reagent method, as described above.

2.3.3 Reverse transcription
After RNA isolation, reverse transcription was performed using the quantified RNA
samples. RNA was diluted in 0.1% DEPC water for a total of 0.5 μg of RNA in 11.5 µL.
Random primers (20 µM) were added in the mixture (1 µL) and heated to 65 °C for 5
minutes, followed by cooling on ice for 3 minutes. Reverse transcription master mix (4 µL
of 5x FirstStrand buffer, 2 µL of 0.1 M DTT, 1 µL of 10 mM dNTP, and 0.5 µL of 200
U/µL M-MLV reverse transcriptase) was then added to each sample. Samples were
incubated at 37 °C for 4 hours. M-MLV reverse transcriptase was inactivated by incubating
the cDNA mixture at 95 °C for 5 minutes, and cDNA was stored at -20 °C for subsequent
qPCR.

2.3.4 Quantitative real-time PCR
Following reverse transcription, the resulting cDNA was diluted with water, and then
incubated at 65 °C for 5 minutes. Real-time quantitative PCR amplification was performed
for each cDNA sample using: 2.5 µL ddH2O, 5 µL 2x EvaGreen qPCR MasterMix, 0.5 µL
of primer for gene of interest (Forward + Reverse; 20 µM), and 2 µL of cDNA. The internal
control gene was 28S ribosomal RNA. For 28S rRNA detection, the cDNA was diluted 500
times. Primers were designed to amplify the target genes, as shown in Table 2.1. Eppendorf
MasterCycler Realplex2 (Eppendorf, Hamburg, Germany) was used to amplify qPCR
mixtures for 35 cycles. The standard curve method was used to derive the gene of interest
mRNA content. The relative mRNA quantity of target genes to the internal control were
derived using a comparative CT method.
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Table 2.1. Forward and reverse primer sequences and specific annealing
temperature for genes of interest.
Gene of interest
(Accession #)
TNF-α
(NM_013693.3)
28S
(NR_003279.1)
IL-6
(NM_031168.2)
IL-1β
(NM_008361.4)
RGS2
(NM_009061.4)

Annealing
Primer sequence
Temperature
61 °C
Forward 5’-CGGCATGGATCTCAAAGACA-3’
Reverse 5’-CTTGACGGCAGAGAGGAGGT-3’
61 °C
Forward 5’-GCCTCACGATCCTTCTGACC-3’
Reverse 5’-AACCCAGCTCACGTTCCCTA-3’
61 °C
Forward 5’-CAAAGCCAGAGTCCTTCAGAG-3’
Reverse 5’-ATGGTCTTGGTCCTTAGCCAC-3’
63 °C
Forward 5’-ACAAGGAGAACCAAGCAACGA-3’
Reverse 5’- GCTGATGTACCAGTTGGGGAAC -3’
60 °C
Forward 5’-CATTTGATGAACTGCTGGCCA-3’
Reverse 5’-GCAGCCACTTGTAGCCTCTT-3’

TNF-α ELISA
Inflammatory cytokine TNF-α levels in plasma and cell media treated with vehicle or LPS
for 4 hours were detected using Mouse TNFα ELISA Ready-SET-Go kit (eBioscience, San
Diego, California), following the manufacturer’s protocol.
Total protein levels in cardiomyocyte cultures were determined by Lowry protein assay.
The protein standard curve was extrapolated from bovine serum albumin (BSA) standards.
Samples were read using a SpectraMax M5 (Molecular Devices, San Jose) and SoftMax
Pro software. TNF-α levels in the cardiomyocyte culture media were normalized to total
protein levels.

NF-B activity
2.5.1 Nuclear protein extraction
WT and RGS2-/- mice were treated with LPS or saline (4 mg/kg, IP) for 0.5 hour. Left
ventricles were collected and used in the extraction of nuclear protein. To each tissue
sample, 800 µL of Buffer A (10 mM HEPES pH7.9, 1.5 mM KCl, 10 mM MgCl2, 0.5 mM
DTT, 0.1% NP40, 1 mM PMSF) was added. Tissues were homogenized using a mechanical
homogenizer, and samples were incubated on ice for 30 minutes. Samples were centrifuged
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at 5,000 x g for 10 minutes at 4 °C. The supernatant containing cytoplasmic proteins was
discarded. Pellets were resuspended and washed with Buffer A and centrifuged again. After
aspirating the supernatant, pellets were resuspended in 200 µL of Buffer B (20 mM HEPES
pH 7.9, 25% glycerol, 420 mM NaCl, 1.2 mM MgCl2, 0.2 mM EDTA, 0.5 mM DTT, 0.5
mM PMSF) and sonicated using a Sonic Dismembrator Model 100 (Fisher Scientific,
Waltham, Massachusetts). Samples were incubated on ice for 30 minutes, then centrifuged
at 16,000 x g for 30 minutes at 4 °C. Supernatant containing nuclear protein was collected.
Nuclear protein was quantified using Lowry protein assay, and stored at -80 °C.

2.5.2 NF-B ELISA
NF-ᴋB (p65) relative binding activity was detected using an ELISA kit (Abcam,
ab133112), according to the manufacturer’s protocol. Briefly, nuclear protein samples
were loaded to a plate, coated with a specific double stranded DNA sequence containing
the NF-ᴋB response element. As well, nonspecific binding buffer, positive control, and
competitive inhibitor were each loaded to a well. NF-ᴋB was specifically bound by the
addition of a primary antibody. An HRP-conjugated secondary antibody was added, and
the assay was read at 450 nm using a SpectraMax M5 (Molecular Devices, San Jose) and
SoftMax Pro software.

Western Blotting
2.6.1 Protein lysis from LV tissues
Protein was extracted from left ventricular tissue from mice treated for 0.5 hour with LPS
(4 mg/kg). Tissues were washed with cold PBS and minced mechanically in lysis buffer
on ice using a tissue grinder. Samples were centrifuged at 5,000 x g at 4 ˚C for 5 minutes
to separate tissue and cells from protein lysate. Protein concentration was quantified using
Lowry assay, and the protein standard curve was extrapolated from bovine serum albumin
(BSA) standards. Protein samples were read using a SpectraMax M5 (Molecular Devices,
San Jose) and SoftMax Pro software. Loading protein samples were made for 75 µg
protein/sample, diluted with lysis buffer.
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2.6.2 Protein lysis from cardiomyocytes
Protein was lysed from cardiomyocyte cultures treated with LPS (5 µg/ml) for 0.5 hour.
After washing cells with PBS, cells were mechanically disrupted with a pipette in lysis
buffer and the lysate transferred into Eppendorf tubes. The lysate was then sonicated using
a Sonic Dismembrator Model 100 (Fisher Scientific, Waltham, Massachusetts). Cells were
separated from the protein lysate through centrifugation (5,000 x g at 4 ˚C for 5 minutes).
Protein concentration was quantified using a Lowry assay, as described above.

2.6.3 Immunoblotting
Loading dye (4x: 0.125 M Tris-HCl pH 6.8, 20% glycerol, 0.4% SDS, 0.1% 2mercaptoethanol, 0.1% bromophenol blue) was added to each sample, and samples were
held for 5 minutes at 95˚C. Seventy-five µg of protein was loaded onto an 8% SDSpolyacrylamide gel. The gel was run at 100 V for 2.5 hours. Then, proteins were wet
transferred to a 0.45 µm polyvinylidene difluoride (PVDF) membrane at 100 V for 1 hour.
The membrane was blocked in 5% skim milk for 1 hour at room temperature on a rotator.
Then, the membrane was incubated with primary antibody overnight at 4˚C, on a rotator.
The membrane was washed with 0.1% Tween-20 tris-buffered saline (TBS-T) and then
incubated with secondary antibody. The membrane was washed with TBS-T and visualized
on film or by fluorescence on Odyssey (LI-COR Biosciences, Lincoln, Nebraska). For film
visualization, a solution of part A (1:5) and part B (1:50) of automatic X-ray developer
concentrate (White Mountain Imaging, Webster, New Hampshire) was used to develop the
film in the dark. The signal was quantified by densitometry reading using FluorChem 8000.
The dilution of primary and secondary antibodies used are shown in Table 2.2.
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Table 2.2. Primary antibody concentrations and the corresponding secondary
antibody concentrations used for immunoblotting.
Primary antibody

Secondary antibody

1:1000 Phospho-ERK1/2

1:1000 Goat anti-Rabbit Alexafluor 680

(#9101, Cell Signaling Technologies, (#926-68021, LI-COR Biosciences, Lincoln,
Danvers, MA)

Nebraska)

1:1000 Total-ERK1/2
(#sc-94, Santa Cruz Biotechnology,
Dallas, TX)
1:1000 Phospho-p38 MAPK

1:1000 Goat anti-Rabbit Alexafluor 680

(#9211, Cell Signaling Technologies, (#926-68021, LI-COR Biosciences, Lincoln,
Danvers, MA)

Nebraska) OR;

1:1000 Total-p38 MAPK
(#9212, Cell Signaling Technologies, 1:1000 Goat anti-Rabbit-HRP
Danvers, MA)

(#170-6515, Bio-Rad, Hercules, California)

1:1000 α-actinin

1:1000 Goat anti-mouse-HRP

(#A7811, Sigma, St. Louis, MO)

(#170-6516, Bio-Rad, Hercules, California)
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Echocardiography
Echocardiography was performed on WT and RGS2-/- mice using the Vevo 2100 HighResolution Imaging System (FUJIFILM VisualSonics, Toronto) for a non-invasive
visualization of the left ventricle.
First, mice were pre-anaesthetized in a chamber, using 3.0% isoflurane gas. Fur was
removed from the chest area using a small amount of hair-removal cream (Nair). Mice
were quickly moved from the chamber and placed in the supine position on a heated
electrode platform (temperature 37 °C) with their noses in a respirator used to deliver 0.51.5% isoflurane (for anesthesia maintenance). The mice were secured to the platform, with
their paws over the electrode surface pads so that the electrocardiography (ECG) could be
recorded. Electrode cream (Parker Labs, NJ, USA) was used to enhance the conductivity
between their paws and the electrode pads. Pre-heated Aquasonic ultrasound transmission
gel (Parker Labs, NJ, USA) was applied copiously on the chest over the heart, and the LV
was visualized using the MS250S transducer probe (FUJIFILM VisualSonics). The heart
was first visualized in the parasternal long axis view (PSLA). PSLA visualization was
controlled by capturing the LV chamber at its widest diameter with a clear view of the
aortic outflow and the apex. The probe was then turned 90˚ to visualize LV short-axis (SA).
M-mode two-dimensional image captures were taken for each mouse. SA visualization was
standardized among the mice by imaging the heart at the level where the papillary muscles
could be detected. This also ensured the LV was imaged at the widest diameter. Each
video/image capture was taken at a heart rate of 450-500 beats per minute (BPM) and body
temperature around 37 ˚C, which allowed consistency between individual animals and was
close to the awake physiological conditions of the mouse.
SA M-mode analysis was performed by marking the left ventricular anterior wall (LVAW),
left ventricular internal dimension (LVID), and left ventricular posterior wall (LVPW) at
both diastole and systole for three continuous heart cycles. Heart rate (HR) was determined
from the continuous three heart cycles. Left ventricular ejection fraction (EF), fractional
shortening (FS), LV anterior wall (AW) mass, and LV volume at systole and diastole (vol;s
and vol;d) were calculated from SA M-mode analysis. Stroke volume (SV) was calculated
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as the difference between LV;d and LV;s, and cardiac output (CO) was calculated as CO
= HR x SV. All measurements were performed on the Vevo 2100 Imaging System.

Statistical analysis
Data are presented as mean ± standard error of the mean (SEM). Body weight and litter
size were analysed using unpaired Student’s t-test. Cardiac function parameters detected
by echocardiography were analyzed using repeated measures two-way analysis of variance
analysis (ANOVA), followed by Bonferroni’s multiple comparisons test. All other data
were analysed using two-way ANOVA followed by Tukey’s post-hoc test. Statistical
significance level was set at α = 0.05. Grubbs test was used to detect for outliers, with α =
0.05. Graphpad Prism (GraphPad Prism, version 5.0, CA, USA) was used for analysis and
graphing of the results.
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Results
Body weight and litter size

WT and RGS2 deficient mice were used throughout in vivo experiments to assess the role
of RGS2 in inflammatory cytokine release during endotoxemia. Male mice, 3-5 months
old, were used. As well, P0 mice of both sexes were used for isolation of cardiomyocytes.
RGS2 limits Gαq- and Gαs-coupled GPCR signaling and has been implicated in the cellular
stress response.124,168 As it is ubiquitously expressed, we wanted to first assess the
phenotype of RGS2-/- mice. We found that RGS2-/- mice had a lower average body weight
than WT mice by 18.6% (Figure 3.1). We also found that RGS2-/- mice had significantly
smaller litters than WT mice (Figure 3.2, P<0.001). These results are consistent with
previous studies that showed lower body weight and smaller litter sizes in RGS2-/mice.169,170
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Figure 3.1. Body weight (g) of WT and RGS2-/- mice. Mice used were 3-5 months old.
Data are presented as individual values and their mean ± SEM. n = 10 mice per group.
**P<0.01 vs. WT.
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Figure 3.2: Litter sizes of WT and RGS2-/- mice. Presented are individual values and
average number of pups per litter ± SEM. n = 18 per group. ***P<0.001 vs. WT.

RGS2 mRNA levels in the heart during endotoxemia
RGS2 is implicated in many physiological and cellular processes, including blood pressure
regulation and cardiac hypertrophy.135,136 To assess the effects of LPS stimulation on RGS2
expression, we analyzed RGS2 mRNA levels using qPCR. Previous studies investigating
agonist stimulated RGS2 expression used time points from 0.5-12 hours.171 Specifically,
in cardiomyocytes, RGS2 mRNA levels were analyzed after 0.5-3 hours of agonist
treatment.

155,172

Thus, we collected LV tissues from WT and RGS2-/- mice 2 hours after

LPS (4 mg/kg, IP) or saline control treatment. RNA was isolated and reverse transcribed
to be analyzed by qPCR. We found that LPS stimulation in vivo did not affect RGS2 mRNA
expression in the heart in WT mice (Figure 3.3). As expected, RGS2 deficient mice
displayed negligible or no RGS2 mRNA content in the heart.
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Figure 3.3. RGS2 mRNA level in WT LV after LPS treatment in vivo. Mice were
treated hours with LPS (4 mg/kg, IP) or saline control for 2 hours. RNA was isolated from
LV and reverse transcribed to cDNA. qPCR was performed and RGS2 mRNA levels were
normalized to 28S using the standard curve method. Data are presented as individual values
and their mean ± SEM. n = 4-6 mice per group. *P<0.05, **P<0.01 vs. respective WT.
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TNF-α mRNA and protein levels in the heart after LPS
treatment in vivo
To assess the role of RGS2 in inflammatory cytokine release during endotoxemia, the
expression of TNF-α induced by LPS was assessed as an indicator of the inflammatory
response. We treated WT and RGS2-/- male mice with LPS (4 mg/kg, IP) or saline as control
and collected plasma and LV tissues. To assess myocardial TNF-α mRNA levels, LV
tissues were collected from mice 2 hours after LPS or control saline injection and qPCR
analysis was performed.
LPS treatment for 2 hours in WT and RGS2-/- mice showed higher TNF-α mRNA levels
compared to their respective saline controls (P<0.01). Notably, higher TNF-α mRNA
levels were further enhanced in RGS2-/- compared to WT mice (P<0.05), which suggests
that RGS2 has a regulatory role in proinflammatory cytokine release induced by LPS
(Figure 3.4).
To assess the effects on TNF-α mRNA levels, WT and RGS2-/- mice were injected with
LPS (4 mg/kg, IP) and blood was collected via cardiac puncture at 0.5, 2, 4, or 24 hours
after injection. Plasma was isolated via centrifugation. TNF-α was measured by an ELISA.
There was no significant change in plasma TNF-α levels detected at 0.5 hours (Figure 3.5).
In the WT samples, plasma TNF-α plateaued and started to decrease approximately 2 to 4
hours after LPS stimulation. Comparatively, in plasma of RGS2-/- mice, TNF-α levels were
significantly higher after 2 hours (P<0.05) and continued to increase, as shown by the
higher plasma TNF-α level at 4 hours (P<0.01) of LPS treatment. At 24 hours post-LPS
injection, plasma TNF-α levels of both WT and RGS2-/- mice were comparable to control
levels (P>0.05 compared to 0 hour). We found the plasma TNF-α levels for WT mice to
be consistent with previous studies from our lab.33
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Figure 3.4. WT and RGS2-/- LV TNF-α mRNA levels 2 hours after LPS treatment.
Male mice were treated with LPS (4 mg/kg, IP) or saline control for 2 hours. RNA was
isolated from LV and reverse transcribed to cDNA. qPCR was performed and TNF-α
mRNA level was normalized to 28S using the standard curve method. Data are presented
as individual values and their mean ± SEM. n = 7 mice per group. *P<0.05; **P<0.01;
***P<0.001 vs. respective WT or control treatment.
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Figure 3.5. Plasma TNF-α levels in WT and RGS2-/- during endotoxemia. Male mice
were treated with LPS (4 mg/kg, IP) for 0.5, 2, 4, and 24 hours. Blood was collected via
cardiac puncture and plasma was isolated by centrifugation. Plasma TNF-α protein levels
were detected using an ELISA kit. Data are presented as individual values and their mean
± SEM. n = 3-8 mice per group. *P<0.05, **P<0.01, ***P<0.001 vs. respective WT or
LPS stimulation.
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TNF-α mRNA and protein levels in cardiomyocytes
To complement the in vivo model and further investigate the changes observed in Figures
3.4 and 3.5, neonatal cardiomyocytes were isolated from P0 WT and RGS2-/- mice. This
experiment would further clarify if the increases in TNF-α observed in the in vivo model
might derive at least in part from cardiomyocytes. Again, the role of RGS2 in LPSstimulated inflammatory cytokine release was assessed.
Cultured cardiomyocytes were treated with LPS (5 µg/ml) or medium as control for 2
hours. RNA was isolated from the cardiomyocytes, and TNF-α mRNA levels were detected
using qPCR. Similar to the in vivo results, LPS stimulated TNF-α mRNA expression in
both WT and RGS2-/- cardiomyocytes compared to controls (Figure 3.6a, P<0.05). Notably,
LPS-induced TNF-α mRNA levels were further enhanced in RGS2-/- cardiomyocytes
compared to WT (Figure 3.6Error! Reference source not found.a, P<0.01).
To investigate changes in TNF-α release, WT and RGS2-/- cardiomyocytes were treated
with LPS (5 µg/ml) or medium as control for 4 hours. Since global TNF-α release showed
a significant difference between WT and RGS2-/- mice at 4 hours (Figure 3.5), we chose
this treatment period to evaluate any differences between cardiomyocytes isolated from the
two genotypes. An ELISA kit was used to detect TNF-α release in the cell media. Similar
to the in vivo results, higher TNF-α proteins were found to be released into the
cardiomyocyte culture medium when treated with LPS compared to control. This effect
again was exacerbated in the RGS2-/- mice (Figure 3.6b, P<0.001 and P<0.01, respectively).
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Figure 3.6. LPS-induced TNF-α levels in WT and RGS2-/- cardiomyocytes. A) RTqPCR analysis of TNF-α mRNA in WT and RGS2-/- neonatal cardiomyocytes treated with
LPS (5 µg/ml) for 2 hours. n = 5-6 mice per group. B) Detection via an ELISA of TNF-α
release using media collected from WT and RGS2-/- cardiomyocyte cell cultures treated
with LPS (5 µg/ml) for 4 hours. TNF-α levels were normalized to total cell protein levels
as determined by Lowry protein assay. Culture medium was used as control treatment. n =
7-11 mice per group. Data are presented as individual values and their mean ± SEM.
*P<0.05; **P<0.01; ***P<0.001 vs. respective WT or control treatment.
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Interleukin mRNA levels in the heart during
endotoxemia
During septic conditions, proinflammatory cytokines are induced, including IL6 and IL1β. We wanted to assess if RGS2 has a central role in regulating the production of
inflammatory cytokines other than TNF-α. IL-6 and IL-1β have initial peak timepoints
similar to TNF-α in endotoxemic mice, which suggests that an altered mRNA response of
IL-6 and IL-1β may be detectable at 2 hours post-LPS injection.173 Thus, we analyzed the
mRNA levels of these cytokines in LV tissues samples collected from WT and RGS2-/mice 2 hours after LPS (4 mg/kg, IP) treatment or saline control treatments.
Using qPCR analysis, LPS stimulated IL6 mRNA expression in both WT and RGS2-/- mice
(Figure 3.7, P<0.01 and P<0.001, respectively). However, no significant difference was
found between WT and RGS2-/- mice.
Similarly, IL-1β mRNA levels were upregulated in the heart during endotoxemia in both
WT and RGS2-/- mice (Figure 3.8, P<0.01 and P<0.001, respectively). No significant
difference was found between WT and RGS2-/- mice when treated with LPS.
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Figure 3.7. Myocardial IL-6 mRNA levels in WT and RGS2-/- mice after LPS
treatment in vivo. WT and RGS2-/- male mice were treated with LPS (4 mg/kg, IP) or
saline controls for 2 hours. RNA was isolated from LV and reverse transcribed to cDNA.
qPCR analysis was performed, and IL-6 mRNA levels were normalized to 28S using the
standard curve method. Data are presented as individual values and their mean ± SEM. n
= 5-6 mice per group. **P<0.01, ***P<0.001 vs. respective controls.
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Figure 3.8. Myocardial IL-1β mRNA levels in WT and RGS2-/- mice after LPS
treatment in vivo. WT and RGS2-/- male mice were treated with LPS (4 mg/kg, IP) or
saline controls for 2 hours. RNA was isolated from LV and reverse transcribed to cDNA.
qPCR analysis was performed and IL-1β mRNA levels were normalized to 28S using the
standard curve method. Data are presented as individual values and their mean ± SEM. n
= 5-6 mice per group. **P<0.01, ***P<0.001 vs. respective controls.
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Left ventricular cardiac function in endotoxemia
The detrimental effect of LPS on cardiac function was previously shown to be mediated
through the production of proinflammatory cytokines.29 LPS-stimulated proinflammatory
cytokine TNF-α has been suggested to be a main component in cardiac dysfunction.25
Patients with sepsis often have impaired cardiac function, as a consequence of elevated
proinflammatory cytokine levels.30 To investigate whether RGS2 deficiency would
exacerbate cardiac dysfunction, we performed echocardiography on WT and RGS2-/- mice
at baseline and 24 hours after LPS treatment (4 mg/kg, IP; Figure 3.9, Error! Reference
source not found.).
Short-axis M-mode was used to assess cardiac parameters including ejection fraction,
fractional shortening, and LV anterior wall (AW) mass. As well, LVAW, LV internal
dimension (ID), and LV posterior wall (PW), each at end diastole (;d) and end systole (;s),
were measured. Using short axis M-mode analysis, we found that LV ejection fractions of
both WT and RGS2-/- mice were impaired during endotoxemia (
Figure 3.10a, P<0.001 and P<0.01, respectively). At baseline, RGS2-/- mice had a lower
ejection fraction, which was further exacerbated by LPS treatment (
Figure 3.10a, P<0.01 and P<0.05, respectively). A similar trend was detected for LV
fractional shortening, as shown in
Figure 3.10b. LPS treatment resulted in reduced fractional shortening in both WT and
RGS2-/- mice. Notably, LV fractional shortening associated with RGS2 deficiency
weakened cardiac function under both basal and endotoxemic conditions (P<0.01 and
P<0.05 respectively). Stroke volume was calculated as the difference between diastolic and
systolic LV volume, and was significantly lower after LPS treatment in both WT and RGS2/-

mice (Table 3.1, P<0.01 and P<0.001, respectively). Similarly, cardiac output was also

lower after LPS treatment in WT and RGS2-/- mice (Table 3.1, P<0.001). There were no
significant differences in stroke volume or cardiac output between WT and RGS2-/- mice
at baseline and LPS-treated conditions. Finally, no significant differences were found for
heart rate and LV AW mass (Table 3.1, P=n.s.).
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Figure 3.9. Representative short-axis and M-mode images of the left ventricle in WT
and RGS2-/- mice. Cardiac function in WT and RGS2-/- mice was determined using
echocardiography at baseline and 24 hours after LPS (4 mg/kg, IP) treatment. Shown are
LV short axis images at the level of the papillary muscles. LVAW: left ventricular anterior
wall; LVID: left ventricular internal dimension; LVPW: left ventricular posterior wall; d:
end diastole; s: end systole.
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Figure 3.10. LV ejection fraction and fractional shortening in WT and RGS2-/- mice.
Echocardiography was performed in WT and RGS2-/- mice at baseline and 24 hours after
LPS (4 mg/kg, IP) treatment. n = 7 mice per group. A) Ejection fraction and B) fractional
shortening were analyzed using LV short-axis M-mode. Data are presented as individual
values and their mean ± SEM. *P<0.05; **P<0.01; ***P<0.001 vs. respective WT or
baseline condition.
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Table 3.1. Tabular summary of cardiac function in WT and RGS2-/- mice analyzed
by short-axis M-mode echocardiography.

Parameters

Heart Rate (BPM)

WT

RGS2

n=7

n=7

-/-

Baseline

LPS

Baseline

LPS

463.9 ± 16.7

457.6 ± 17.8

435.8 ± 15.7

461.7 ± 12.6

Ejection Fraction (%)

60.3 ± 3.6

41.2 ± 4.2***

44.4 ± 2.0††

29.6 ± 1.9**†

Fractional Shortening (%)

32.0 ± 2.4

20.0 ± 2.4***

21.8 ± 1.2††

13.6 ± 0.9**†

Stroke Volume (μL)

39.4 ± 2.8

24.4 ± 2.8**

35.3 ± 1.6

17.9 ± 1.5***

Cardiac Output (mL/min)

18.2 ± 1.3

11.0 ± 1.3***

15.4 ± 1.0

8.2 ± 0.6***

LVAW;d (mm)

0.8 ± 0.0

0.8 ± 0.1

0.6 ± 0.0

0.9 ± 0.1*

LVAW;s (mm)

1.2 ± 0.1

1.0 ± 0.1

0.9 ± 0.0††

1.0 ± 0.1

LVID;d (mm)

3.9 ± 0.1

3.7 ± 0.2

4.2 ± 0.1

3.8 ± 0.2

LVID;s (mm)

2.7 ± 0.2

3.0 ± 0.2

3.3 ± 0.1††

3.3 ± 0.2

LVPW;d (mm)

0.7 ± 0.1

0.7 ± 0.1

0.6 ± 0.1

0.7 ± 0.1

LVPW;s (mm)

1.1 ± 0.1

0.9 ± 0.1

0.8 ± 0.1

0.8 ± 0.1

82.8 ± 7.2

74.4 ± 8.9

74.0 ± 4.8

82.8 ± 3.5

LV AW Mass (mg)

Echocardiography was performed in WT and RGS2-/- mice at baseline and 24 hours after
LPS (4 mg/kg, IP) treatment. Heart function was measured using short-axis M-mode
analysis. n = 7 mice per group. LVAW: left ventricular anterior wall; LVID: left ventricular
internal dimension; LVPW: left ventricular posterior wall; d: end diastole; s: end systole.
*P<0.05, **P<0.01, ***P<0.001 vs respective baseline condition. †P<0.05, ††P<0.01 vs.
respective WT
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MAPK phosphorylation levels in the heart
Previous studies from our lab showed MAPKs to be mediators in LPS-induced TNF-α
production in the heart.26,61,62,65 ERK1/2 was suggested to have a role in the regulation of
inflammatory cytokine expression.66 Additionally, p38 MAPK α isoform is targeted by
endotoxins in mammalian cells and regulates inflammatory cytokine release.67,68 We
wanted to first confirm that ERK1/2 and p38 are involved in LPS-stimulated inflammatory
cytokine release pathway. Since changes in MAPK activation occur relatively quickly after
LPS stimulation, we extracted protein from LV tissues collected 30 minutes after LPS (4
mg/kg, IP) or saline control treatment.33 We used immunoblotting to detect phosphorylated
relative to total protein levels to assess MAPK activity.
ERK1/2 activity regulates LPS-stimulated TNF-α expression in cardiomyocytes.65 This
study found the ratio of phosphorylated to total ERK1/2 protein signals was higher in LPStreated WT mice compared to control (Figure 3.11Error! Reference source not found.,
P<0.05). Further, there were no significant difference in phosphorylated ERK1/2 levels at
baseline or after LPS treatment between WT and RGS2-/- mice (Figure 3.11, P=n.s.).
Similarly, p38 signaling is enhanced during sepsis, and induces TNF-α production in the
heart.33 Previously, p38 inhibition was shown to alleviate myocardial depression in
endotoxemia.33 We found that while the ratio of phosphorylated to total p38 protein levels
was not significantly higher in LPS-treated WT mice (Figure 3.12, P=n.s.), RGS2-/- mice
had significantly higher phosphorylated p38 levels than WT during endotoxemia (Figure
3.12, P<0.05). These results suggest that p38 mediates the inflammatory response, and it
is regulated by upstream RGS2 activity.
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Figure 3.11. Myocardial ERK1/2 phosphorylation after LPS treatment in vivo. WT
and RGS2-/- mice were treated with LPS (4 mg/kg, IP) or saline control for 0.5 hr. Protein
was extracted from LV. Western blot was performed to detect phosphorylated and total
ERK1/2 protein levels. Data are presented as individual values and their mean ± SEM. N
= 6 mice per group. *P<0.05 vs. respective controls.
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Figure 3.12. Myocardial p38 MAPK phosphorylation after LPS treatment in vivo. WT
and RGS2-/- male mice were treated with LPS (4 mg/kg, IP) or saline control for 0.5 hr.
Protein was extracted from LV. Western blot was performed to detect phosphorylated and
total p38 protein levels. Data are presented as individual values and their mean ± SEM. n
= 5 mice per group. *P<0.05; **P<0.01 vs. respective WT or control treatment.
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PKA-inhibition in cardiomyocytes
MAPK activity can be modulated through its phosphorylation state. PKA is a kinase
upstream of MAPKs that has a role in regulating the activity of p38 and JNK.58 PKA is
also downstream of G protein signaling, and its activity can be induced by Gαs, decreased
by Gαi, and unaffected by Gαq signaling.70 This may be one of the ways that RGS2
modulates TLR4 signaling during endotoxemia. While p38 can be modulated by many
upstream factors, including Gαq-PLCβ-PKC activity, we were interested in investigating
PKA as an inflammatory mediator since it has been shown to be involved in Gαsstimulation of p38 signaling in cardiomyocytes.96 In addition to regulating MAPK activity,
PKA is a central regulator in many biochemical pathways and may affect TNF-α
expression through other signaling factors.174 To investigate its role, we used the PKA
inhibitor H89 to pre-treat cardiomyocytes prior to LPS stimulation.
TNF-α mRNA levels were significantly higher in LPS treated RGS2-/- cardiomyocytes
Figure 3.13, P<0.001). With H89 pretreatment to inhibit PKA, LPS-stimulated TNF-α
mRNA levels were significantly lowered in RGS2-/- cardiomyocytes. There was no
significant difference in TNF-α mRNA levels between DMSO+LPS and H89+LPS
treatments in WT cardiomyocytes.
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Figure 3.13. TNF-α mRNA levels in WT and RGS2-/- cardiomyocytes after PKA
inhibition. WT and RGS2-/- cultures were pretreated with DMSO or H89 (20 µM) for 0.5
hr, followed by LPS (5 µg/ml) stimulation for 2 hours. RNA was isolated from
cardiomyocytes and reverse transcribed to cDNA. qPCR was performed and TNF-α mRNA
levels were normalized to 28S using the standard curve method. Data are presented as
individual values and their mean ± SEM. n = 3-4 mice per group. ***P<0.001 vs.
respective WT, control, or LPS stimulation.
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Relative NF-B activity in the heart
Upon LPS stimulation, the TLR4 signaling cascade activates transcription factors such as
NF-κB and the production of proinflammatory cytokines downstream.19 We wanted to
confirm the role of NF-κB in enhancing inflammatory cytokine release in the heart, and its
involvement as a crosstalk mechanism. PKC has been shown to be upstream of the IKK
complex, and thus may be able to modulate NF-κB activity.159 As well, PKC activity can
be induced by upstream Gαq-PLCβ signaling. Thus, PKC can be modulated by RGS2
activity through the latter’s regulation of Gαq. To investigate NF-κB activity in the heart,
we isolated nuclear proteins from LVs collected 0.5 hours after LPS (4 mg/kg, IP) or saline
control treatment. An ELISA kit was used to detect the presence of p65, a protein
associated in NF-κB heterodimer formation, nuclear translocation, and activation, in the
nuclear protein samples.
In endotoxemia, a relatively higher level of NF-κB activity was detected in WT mice
(Figure 3.14, P<0.05). RGS2-/- mice showed a trend towards higher NF-κB activity during
endotoxemia, but no significant difference was found. Finally, no statistically significant
differences were found between WT and RGS2-/- LV myocardium (P=n.s.).
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Relative NF-B activity
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Figure 3.14. Relative NF-κB activity in WT and RGS2-/- myocardium during
endotoxemia. WT and RGS2-/- mice were treated IP for 0.5 hour with LPS (4 mg/kg, IP)
or saline control. Nuclear protein was extracted from LV and used for ELISA to detect
relative NF-κB activity. Data are presented as individual values and their mean ± SEM, n
= 6 mice per group. *P<0.05 vs. WT control.
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Chapter 4

4

Discussion
Summary

The present study, to our knowledge, is the first to investigate the role of RGS2 in the heart
during endotoxemia. Our study shows that RGS2 deficiency enhances TNF-α
proinflammatory response to LPS stimulation. During endotoxemia, plasma TNF-α levels
were higher in WT mice and higher still in RGS2 deficient mice. Similarly, when assessing
left ventricular TNF-α mRNA levels, we found that RGS2-/- mice had higher levels during
endotoxemia compared to WT mice. This exacerbation of the inflammatory response was
reflected in cultured cardiomyocytes. With LPS treatment, cardiomyocytes showed higher
TNF-α release and mRNA levels compared to untreated conditions. As well, when treated
with LPS, RGS2-/- cardiomyocytes were found to have higher TNF-α release and mRNA
levels than WT cells. RGS2 regulates G protein signaling through GAP-dependent and independent mechanisms. As well, it modulates protein synthesis, independent of its G
protein regulation. This study also investigated possible pathways through which RGS2
affects inflammatory cytokine release during endotoxemia. Previously, we found that p38
is involved in the LPS-TLR4 pathway. This study demonstrated higher LPS-induced p38
phosphorylation in RGS2-/- compared to WT hearts. Finally, this study demonstrated an
exacerbated LV cardiac dysfunction during endotoxemia in RGS2-/- mice. Collectively,
these findings suggest that RGS2 may have a cardioprotective role in endotoxemia by
modulating G protein signaling and downstream MAPK activity.

RGS2 deficiency affects body weight and litter size
RGS2 is expressed in the body globally and is involved in multiple cellular response
pathways.168,170,175 Characteristics of RGS2 deficient mice have been demonstrated in past
studies. Consistent with previous studies, we found that RGS2-/- mice had lower body
weights compared to WT mice when measured at 3 to 5 months of age.169 This weight
difference did not affect RGS2-/- mice from reaching a healthy adult mouse weight.169
RGS2 is involved in adipocyte differentiation and highly expressed in brown adipose
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tissue.175,176 As a result, adipogenesis and function of white adipose tissue and brown
adipose tissue may be weakened in RGS2 deficient mice.169,175
In addition to lower body weight, it was interesting to note that RGS2-/- mice produced
smaller litter sizes. This is consistent with previous reports of the role of RGS2 in
reproduction – namely, it helps maintain mouse egg fertilization by suppressing premature
Ca2+ release.170 While the role of RGS2 in the heart during sepsis has not been studied, a
recent study showed that RGS2 has a bronchoprotective role in LPS induced airway
inflammation.177 However, no clear anti-inflammatory effect was detected as there was no
significant difference found in proinflammatory levels between WT and RGS2-/- mice.177
Other RGS proteins have been implicated in the inflammatory response, including RGS1,
RGS4, RGS10, and RGS16.178–182 In periodontal tissue, RGS10 knockdown reduced local
proinflammatory cytokine expression.181 RGS10 also regulates TNF-α levels in ovarian
cancer cells through a Gαi-independent mechanism.180 Similarly, RGS16 knockdown
enhances proinflammatory cytokine expression, and overexpression reduces the
inflammatory response in monocytes.179 In sepsis, RGS4 and RGS16 levels were enhanced
in the heart corresponding with decreased PLC activity.182 Similarly, Panetta et al. found
RGS1 and RGS16 to be upregulated in the heart and aorta of septic animals, suggesting a
role in amplifying sepsis-mediated signaling pathways.178 However, the role of RGS2 in
the heart in sepsis is not clear.

RGS2 deficiency enhances the TNF-α proinflammatory
response during endotoxemia
To investigate the role of RGS2 in inflammatory cytokine release during endotoxemia, we
wanted to first examine if LPS stimulation changes RGS2 expression in the heart using
qPCR analysis. Predictably, RGS2 mRNA was barely detected in RGS2-/- mice. Further,
there was no significant difference in RGS2 mRNA expression in the heart of WT mice
with or without endotoxemia. However, our assessment of RGS2 mRNA at 2 hours may
be a false negative result, given that previous studies have indicated RGS2 is an early gene
that is upregulated immediately and transiently. This was demonstrated by Grant et al.,
showing RGS2 mRNA upregulation by Ang II peaks at around 1 hour, so it could be
possible that our results only assessed RGS2 expression during the downward phase.183
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While no studies to date have shown endotoxemia affects RGS2 mRNA expression in the
heart, studies have shown that RGS2 expression is downregulated in murine macrophages
after LPS treatment.184,185 LPS was also shown to affect the expression of other RGS
proteins: RGS1 and RGS16 were upregulated in dendritic cells, RGS14 and RGS18
expression decreased in dendritic cells, RGS1 showed a biphasic response in macrophages,
and RGS4 and RGS16 expression transiently increased in cardiomyocytes.182,184,186 This
suggests that RGS2 levels are regulated depending on cell type, and our results indicate
that RGS2 mRNA expression in the heart is not affected by LPS stimulation. Additionally,
RGS2 protein levels increased after digoxin treatment while mRNA levels were not altered,
due to inhibition of RGS2 protein degradation.157 While we tried to detect relative RGS2
protein content in the heart of WT and RGS2-/- mice, the immunoblot analysis did not work
as we could not visualize the RGS2 antibody (not shown). Future experiments are required
to assess RGS2 protein levels in the heart.
In our study, the time course of plasma TNF-α levels was studied after LPS injection,
showing the highest plasma TNF-α levels at 2 hours in WT mice, which was consistent
with previous studies.173 In comparison, plasma TNF-α levels were significantly higher 2
and 4 hours after LPS treatment in RGS2-/- mice. Thus, global TNF-α levels are higher in
endotoxemia in RGS2-/- mice, suggesting that RGS2 may have a regulatory role in
proinflammatory response. This effect may be specific to an LPS-induced TNF-α response
or possibly bacterial infection as loss of RGS2 impacts T-cell proliferation and reduces IL2 levels in response to a viral infection.162
TNF-α expression contributes to cardiovascular dysfunction in sepsis.33,71 Accordingly,
TNF-α mRNA expression was analyzed in the heart of mice in the present study. Similar
to changes in plasma TNF-α levels, we detected higher TNF-α mRNA expression in the
LV tissues of RGS2-/- mice compared to WT during endotoxemia. This novel finding is in
sharp contrast with a recent study showing that LPS-induced TNF-α expression in
bronchoalveolar lavage fluid was not significantly different between RGS2-/- and WT
mice.177 This may suggest that while RGS2 is present in various tissues, its role during
endotoxemia may differ depending on the tissue type.129,133,177
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To complement our in vivo study, experiments were carried out in primary neonatal
cardiomyocytes. Consistent with our previous studies,33 LPS induced TNF-α expression in
WT cardiomyocytes. Notably, a significantly higher LPS-induced TNF-α production was
found in RGS2-/- compared to WT cardiomyocytes. The results show that RGS2 inhibits
LPS-induced inflammatory response in cardiomyocytes.

Interleukin release is not affected by RGS2 deficiency
Exacerbated proinflammatory cytokine release is associated with the dysregulated immune
response in sepsis. In addition to TNF-α, other inflammatory cytokines involved in the
septic response include interleukins, such as IL-1β and IL-6. Both interleukins were shown
to be involved in sepsis, in both animal models and human studies.37,187 In the current study,
WT mice also had significantly higher interleukin levels in endotoxemia. However, for
both IL-1β and IL-6, no significant difference was found between WT and RGS2-/- mice
during endotoxemia. One reason that interleukin levels were not significantly different
between the two genotypes is possibly because peak mRNA levels for the interleukins may
occur at around 4-6 hours after LPS injection,37 which could be assessed in future studies.
As well, while interleukins act synergistically with TNF-α during sepsis, they are activated
through a different pathway than that of TNF-α. As well, the lack of significant difference
in myocardial interleukin levels between WT and RGS2-/- mice may be due to different
autocrine and paracrine signaling pathways of TNF-α, IL1β, and IL-6. For example, in
human astrocytoma cells, PKC and reactive oxygen intermediates (ROIs) were involved in
IL-6 and TNF-α gene expression induced by IL-1β. However, protein tyrosine kinases only
aided in IL-6 expression.188 The present study suggests that IL-1β and IL-6 expression are
not regulated by RGS2 in the heart during endotoxemia.

Cardiac dysfunction is exacerbated in RGS2 deficient
mice
Cardiac dysfunction is associated with inflammation in a feedforward manner.189,190 As
part of this detrimental loop, peripheral tissues release inflammatory signaling molecules
that mediate the progression of heart failure. Long term exposure to inflammatory
cytokines also exacerbates myocardial damage and enhanced proinflammatory expression
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are indicators of mortality in severe heart failure patients.189,191 As part of the feedforward
cycle, heart failure further stimulates inflammation in cardiac cells. This is activated by
stress signals in the damaged cells, which cause further inflammatory responses in
peripheral tissues, including adipose tissue, spleen, and bone marrow.190 Because of this
harmful loop, understanding the pathophysiology is beneficial in order to regulate the early
immune response to avoid sepsis and heart failure. Using echocardiographic imaging
followed by M-mode analysis, we found that cardiac function was impaired during
endotoxemia with decreased ejection fraction, fractional shortening, cardiac output, and
stroke volume in both WT and RGS2-/- mice. Heart rate was not significantly different
between the treatments, which suggests that the impaired cardiac function is not due to
varying heart rates. Notably, LV ejection fraction, and fractional shortening, were lower
further in RGS2-/- mice compared to WT at baseline and during endotoxemia. Our results
show that RGS2 has an important role in maintaining cardiac function during endotoxemia.
In contrast to our data, a past study using RGS2-/- mice showed no differences in cardiac
function under basal conditions; however, they also showed a cardioprotective role of
RGS2.152 This discrepancy may be because we performed echocardiography on
anesthetized mice compared to conscious mice. Awake mice may undergo high stress
conditions when echocardiography is performed, which could interfere with the cardiac
function measurement. As well, there was a difference in the equipment used – our
transducer allowed for clearer imaging of the heart, comparatively. Future experiments can
investigate cardiac function using myocardial strain analysis, which is an even more
sensitive method that has been proposed as a measure of monitoring cardiac function in
sepsis mouse models.192

p38 may be involved in a crosstalk mechanism
This study investigated the specific signaling mediators by which RGS2 regulates the
inflammatory response in sepsis. MAPKs are signaling mediators critical to LPS-induced
TNF-α production, and MAPK activity is induced in the heart during sepsis.26,61–63
Specifically, ERK1/2 and p38 MAPKs modulate TNF-α expression in cardiomyocytes, and
function as positive regulators of the proinflammatory cytokine release.33,61,65 Similarly,
our study found that LPS induces ERK1/2 and p38 phosphorylation in the LV myocardium.
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RGS2 deficiency did not affect ERK1/2 phosphorylation in endotoxemia. In contrast, LPSinduced p38 phosphorylation was enhanced in RGS2-/- mice. Previous studies have shown
that inhibiting p38 signaling decreases myocardial TNF-α expression and improves cardiac
function during endotoxemia.33,58.
While our study did not show ERK1/2 phosphorylation to be affected by RGS2, a previous
study indicated that RGS2 overexpression suppresses oxytocin-stimulated activation of
ERK1/2 and RGS2 silencing resulted in increased signaling via ERK1/2.193 While ERK1/2
and p38 are parallel signaling MAPKs and are often found to function in tandem, they are
also involved in many broad physiological processes. ERK1/2 and p38 are involved in
crosstalk processes that may affect their individual phosphorylation. For example,
increased expression of JNK/c-fos resulted in lower phosphorylation of ERK1/2 and p38,
which leads to lower TNF-α expression in LPS-stimulated cardiomyocytes.61 Additionally,
p38 is mainly regulated by Gαs and Gαq-signaling, but not Gαi, whereas ERK1/2 can be
regulated by Gαi.70 Since RGS2 has a low affinity for Gαi, that may be another reason why
ERK1/2 activity is not affected by RGS2 deficiency. RGS2 also functions on the level of
G protein signaling, and MAPK activity can be affected by mediators other than RGS2.
While our study may suggest that p38 and ERK1/2 are regulated differently by RGS2
during endotoxemia, future studies should investigate the MAPK phosphorylation levels
in primary neonatal cardiomyocytes in addition to LV tissues.
To investigate how RGS2 modulates p38 activity, this study assessed the role of PKA,
which is an upstream kinase that can phosphorylate MAPKs.58 This study did not detect
any significant differences in TNF-α mRNA levels when PKA was inhibited in WT
cardiomyocytes. We found that PKA inhibition with LPS treatment resulted in lower TNFα expression in RGS2-/- cardiomyocytes. However, because our experiment had a small
sample size, we cannot draw any conclusion on whether PKA is involved in RGS2’s
inflammatory regulation. Our results may also be due to PKA’s broad role in many cellular
processes, including apoptosis and myocardial dysfunction.58,115 As well, p38 can be
activated by many mediators other than PKA, such as Gαq-PLCβ signaling.58 Thus
inhibiting PKA alone may not be enough to determine the role of RGS2 in regulating p38
in endotoxemia.
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Finally, we assessed if RGS2 modulates NF-κB activity induced by LPS. NF-κB is a central
mediator of proinflammatory cytokine expression and can prolong inflammatory
conditions through a feed-forward loop via IKK activity.77,82 IKK complex function can be
regulated by RGS2-mediated PKC.159 Our study showed that LPS induces NF-κB
activation in the heart of WT mice during endotoxemia. This echoes previous papers that
indicate LPS activation of TLR4 induces NF-κB translocation.75 We did not detect any
difference in NF-κB activity between RGS2-/- and WT mice, suggesting that RGS2 may
not regulate NF-κB activity. The lack of significance may be due to the large variability
within the RGS2-/- group, and future experiments should aim to reduce the effect of
variation by increasing sample size. Additionally, NF-κB can be induced by numerous
signaling factors.77 Specifically, Gαs signaling and Gαq signaling have conflicting effects
on NF-κB activity – Gαs-cAMP-PKA activity inhibits NF-κB, whereas the βγ-subunit and
Gαq induces NF-κB.194 Thus, it may be hard to determine the exact effect of RGS2 on NFκB without inhibiting or stimulating either Gαs or Gαq signaling. Presently, our study
indicates that NF-κB is not regulated by RGS2 during endotoxemia.

Limitations and future directions
Confines to the present study design include using globally knocked-out RGS2 mice to
investigate inflammatory response in septic conditions in the heart. While we will isolate
the effects in cardiomyocytes by using an in vitro model, it may be prudent to follow up
the study using cardiomyocyte-specific RGS2 knockout mice. As well, LPS treatment is
used to model sepsis; however, endotoxemia conditions does not accurately reflect full
clinical sepsis as it is only a component of Gram-negative bacteria and not live bacteria.
Furthermore, only a third of septic cases were found to have originated from Gramnegative bacterial infections.3 Mice have been shown to be less sensitive to LPS than
humans, even in more sensitive strains, and expresses varied endotoxemia gene profiles.20
Thus, while our LPS model is sufficient for investigating the pathophysiology of sepsis,
follow-up studies using other sepsis models (e.g. cecal ligation puncture, pneumoniainduced) may help enhance the clinical applicability of the results.20 This study can also be
replicated using human cells (e.g. human induced pluripotent stem cell derived
cardiomyocytes) to confirm that cell signalling pathways and inflammatory response are
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similar between species. This can be verified by investigating the proteomic expression of
the environment in mouse and human cells.
While the current study looked at the overall role of RGS2 in the inflammatory response,
future experiments can assess the involvement of each distinct RGS2 function. For
example, we can determine whether RGS2 regulates proinflammatory cytokine production
mainly via Gαs, Gαq, or eIF2B mechanism. This would also clarify how RGS2 modulates
downstream mediators such as NF-κB, which is regulated differently by both Gαs and Gαq
signaling.194 Additionally, future experiments may investigate whether mortality and the
LD50 of LPS is impacted by RGS2 deficiency. Finally, since RGS2 is highly expressed in
the immune system, a follow-up study may examine the contribution of RGS2 to
pathogenic changes in sepsis.

Conclusions
To our knowledge, the present study is the first to show that RGS2 limits inflammatory
cytokine expression in endotoxemia. In response to LPS, RGS2-/- mice have higher plasma
and LV myocardial TNF-α levels. Whereas in WT mice, plasma TNF-α levels peak at
around 2 hours after LPS treatment, RGS2-/- mice had increasing TNF-α levels at 4 hours.
RGS2-/- mice had lower cardiac function than WT at baseline, and RGS2 deficiency further
exacerbated cardiac dysfunction during endotoxemia. Our results suggest that p38 is a
proinflammatory mediator that is regulated by RGS2 during endotoxemia. (Figure 4.1).
While further studies need to be conducted to investigate the specific signaling mechanism
through which RGS2 regulates proinflammatory cytokine expression, our study suggests a
cardioprotective role of RGS2 in inhibiting proinflammatory signaling in sepsis. The
present study suggests a novel therapeutic target for clinical treatment of sepsis. While
targeting RGS2 may be complicated due to its central role in many biochemical pathways,
this study illuminates possible secondary effects of current clinical drugs, such as the
cardiotonic drug digoxin, which upregulates RGS2 activity.157 This study advances the
understanding of sepsis pathogenesis and provides a new therapeutic strategy to combat
the high global mortality rate of sepsis.
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Figure 4.1: Schematic of RGS2 regulation of TNF-α expression during endotoxemia
in the heart. TLR4 is activated by LPS, resulting in downstream phosphorylation of p38
MAPK which mediates the production of TNF-α. The induced p38 activity may be
inhibited by RGS2 activity, which suppresses possible upstream proinflammatory
mediators including PKA, PKC, and Ca2+ (indicated by purple dashed arrows). Purple
question marks indicate future experiments to investigate the involvement of each distinct
RGS2 function (i.e. whether RGS2 regulates proinflammatory cytokine production mainly
via Gαs, Gαq, or eIF2B-regulated protein synthesis mechanism).
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